Related content

Long-term treatment with finasteride in men with symptomatic benign prostatic hyperplasia: 10-year follow-up

By Lam J.S.   Romas N.A.   Lowe F.C.  

Urology, Vol. 61, Iss. 2, 2003-02 ,pp. : 354-358

Elsevier

Access to resources Recommend Favorite

Meta-analysis of clinical trials of Permixon in the treatment of symptomatic benign prostatic hyperplasia

By Boyle P.   Robertson C.   Lowe F.   Roehrborn C.  

Urology, Vol. 55, Iss. 4, 2000-04 ,pp. : 533-539

Elsevier

Access to resources Recommend Favorite

Is the minimally invasive treatment as good as transurethral resection for benign prostatic hyperplasia?

By Zani Emerson   Netto Nelson  

International Urology and Nephrology, Vol. 39, Iss. 1, 2007-03 ,pp. : 161-168

Springer Publishing Company

Access to resources Recommend Favorite

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia

By Roehrborn C.G.   Oesterling J.E.   Auerbach S.   Kaplan S.A.   Lloyd L.K.   Milam D.F.   Padley R.J.  

Urology, Vol. 47, Iss. 2, 1996-02 ,pp. : 159-168

Elsevier

Access to resources Recommend Favorite

First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia

By Marks L.S.   Roehrborn C.G.   Gittelman M.   Kim D.   Forrest J.   Jacobs S.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 888-893

Elsevier

Access to resources Recommend Favorite